For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240215:nRSO1910Da&default-theme=true
RNS Number : 1910D Benchmark Holdings PLC 15 February 2024
15 February 2024
Information within this announcement is deemed by the Company to constitute
inside information under the Market Abuse Regulations (EU) No. 596/2014
Benchmark Holdings plc
("Benchmark", the "Company" or the "Group")
Q1 Results
(Three months ended 31 December 2023)
Good performance in Genetics and Advanced Nutrition in line with Management's
expectations
Actions taken to transition to new business model in Health
In compliance with the terms of the Company's unsecured Green bond, which
requires it to publish quarterly financial information, Benchmark, the
aquaculture biotechnology business, announces its unaudited results for the
three months ended 31 December 2023 (the "Period"), which constitute the first
quarter for the fiscal year ("FY") 2024. All Q1 FY23, Q4 FY23 and Q1 FY24
figures quoted in this announcement are based on unaudited accounts.
Financial highlights
· Q1 FY24 revenues were £40.5m, 26% below a particularly strong Q1
FY23 (-19% CER), but 11% above Q4 FY23, maintaining quarterly momentum
o Genetics revenues were £15.2m, a solid performance against a strong Q1
FY23 when the Company benefitted from supply constraints of salmon eggs in the
market (Q1 FY23: £21.4m)
o Advanced Nutrition revenues were £19.3m, 13% above Q4 FY23 reflecting a
solid performance in the context of continuing soft market conditions (Q1
FY23: £22.7m)
o Health revenues of £6.1m were lower than anticipated as a result of
biological challenges faced by certain customers' fish stock which led to the
cancellation of orders of Ectosan® Vet and CleanTreat® in December (Q1 FY23:
£10.4m)
· Gross profit margin maintained at 45% (Q1 FY23: 45%)
· Q1 FY24 Adjusted EBITDA excluding fair value movements from
biological assets was £7.5m (Q1 FY23: £12.5m) due to lower revenues
partially offset by a reduction in operating costs
· Adj. EBITDA margin excluding fair value movements from biological
assets of 18% (Q1 FY23: 23%); margin improvements in Genetics and Advanced
Nutrition offset by Health
o Genetics Adj. EBITDA margin excluding FV movements in biological assets
increased to 22% (Q1 FY23: 19%)
o Advanced Nutrition Adj. EBITDA margin increased to 24% (Q1 FY23: 23%)
o Excluding Health, Group Adj. EBITDA margin excl. fair value movements from
biological assets of 20% (Q1 FY23: 19%)
· Cash, liquidity and net debt:
o Cash of £24.2m and liquidity of £36.4m (cash and available facility)
o Net debt excluding lease liabilities of £57.5m (30 September 2023:
£45.6m)
Operational highlights
· Genetics - Solid performance in the core salmon business and progress
in growth vectors
o Post period end launch of a new product portfolio in salmon genetics,
strengthening the Company's offering and demonstrating its ongoing commitment
to innovation
o Growing commercial traction in Chile with revenue growth underpinned by
new customers and repeat orders and strong progress towards profitability
o Successful integration of shrimp activities across Genetics and Advanced
Nutrition driving commercial synergies and cost savings
o No impact on the Company's ability to meet customer demand for salmon eggs
following the detection of ISA virus (Infectious Salmon Anaemia) in a single
tank at Salten facility post period end. There have been no further signs ISA
at the facility or in the specific tank from which the fish originated
· Advanced Nutrition - Strong performance in Europe and well positioned
for market recovery
o Strong performance in Europe from marine fish, offset by soft shrimp
markets particularly in Asia
o Successful commercialisation of SnappArt post launch with initial supply
sold-out, demonstrating the Company's successful innovation and commercial
capability
o Ongoing commercial focus and actions to improve operational efficiency,
including equipment improvements, place the business in a strong position for
market recovery
· Health - Significant steps taken to transition to new business model
for Ectosan® Vet and CleanTreat®
o Further progress made towards development of a new configuration and
business model for Ectosan® Vet and CleanTreat® aimed at reducing
infrastructure costs
§ Continued progress on wellboat configuration and steps to develop a third
configuration based on a barge
o Streamlining of existing infrastructure and organisation with
demobilisation of one of the two CleanTreat® units, leading to cost savings
Current trading and outlook
Trading in line with management's expectations for the full year underpinned
by good revenue visibility in Genetics, continuing positive performance in
Advanced Nutrition and focus on profitable growth with actions to manage costs
and cash in Health as the business transitions to a new configuration for
Ectosan® Vet and CleanTreat®.
Financial Summary - continuing operations
£m Q1 FY24 Q1 FY23 % AER % CER(**) Q4 FY23 FY23
Restated (full year)
Revenue 40.5 54.4 -26% -19% 36.6 169.5
Adjusted
Adj. EBITDA excluding fair value movement in biological asset 7.5 12.5 -40% -34% 9.2 35.6
Adjusted EBITDA(1) 6.7 11.3 -41% -35% 7.4 35.5
Adjusted Operating Profit/(Loss)(2) (0.2) 6.2 n.m. n.m. 2.1 14.6
Statutory
Operating loss (4.4) 0.3 n.m. n.m. (2.3) (5.3)
Profit/(loss) before tax (7.2) 0.6 n.m. n.m. (7.3) (12.7)
Loss for the period (7.6) (0.7) n.m. n.m. (13.5) (21.6)
Basic loss per share (p) (1.03) (0.18) (1.87) (3.16)
Net debt(3) (74.6) (61.4) (65.5) (65.5)
Net debt excluding lease liabilities (57.5) (37.9) (45.6) (45.6)
Business Area summary
£m Q1 FY24 Q1 FY23 % AER % CER(**) Q4 FY23 FY23
(full year)
Revenue
Advanced Nutrition 19.3 22.7 -15% -7% 17.1 78.5
Genetics 15.2 21.4 -29% -23% 16.9 65.5
Health 6.1 10.4 -42% -39% 2.6 25.5
Adjusted EBITDA(1)
Advanced Nutrition 4.6 5.3 -13% -8% 3.5 18.4
Adj. EBITDA Margin (%) 24% 23% 20% 23%
Genetics 2.5 2.9 -15% -5% 5.4 15.7
Genetics excluding fair value movements in biological assets 3.3 4.1 -19% -9% 7.2 15.8
Adjusted EBITDA Margin (%) excl. FV movements in biological asses 22% 19% 42% 24%
Health 0.6 4.1 -86% -84% (0.9) 4.8
*Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates
(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation,
amortisation, and impairment), before exceptional items
(2) Adjusted Operating Profit is operating gain or loss before exceptional
items and amortisation of intangible assets excluding development costs
(3) Net debt is cash and cash equivalents less loans and borrowings
Trond Williksen, CEO, commented:
"We have had a busy quarter where we have maintained momentum in our two
largest business areas and the Group is on track to meet management's
expectations for the year. We have good visibility of revenues in Genetics,
continuing good performance in Advanced Nutrition and have taken actions in
Health to transition to a new business model for Ectosan® Vet and
CleanTreat® which will increase its commercial attractiveness and strengthen
our portfolio of sea lice solutions. We have a busy year ahead and intend to
stay focused to deliver continued progress towards our goals. Longer term, as
a supplier of specialised mission critical solutions to aquaculture producers
worldwide, Benchmark is uniquely positioned in an industry with significant
structural growth trends with significant opportunities ahead."
Analyst / investor presentation and webcast being held today
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a presentation for analysts and institutional investors on
the day at 09.30 GMT (10.30 CET).
The presentation will be held in person at Haakon Vlls Gate 2, Oslo, Norway.
To register your interest, please contact benchmark@mhpgroup.com
(mailto:benchmark@mhpgroup.com)
A live webcast of the presentation will be available for analysts and
investors to join remotely at the following link:
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20240215_10
(https://protect-eu.mimecast.com/s/CyJACoYpmf2nPDnh1_Av-?domain=channel.royalcast.com)
Equity Development webcast for retail investors at 12:00pm UK time
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a second webcast for retail investors and wealth managers at
12.00pm UK time. The webcast is open to all existing and potential
shareholders.
To register please visit:
https://www.equitydevelopment.co.uk/news-and-events/benchmark-q1-investor-presentation-15february2024
(https://protect-eu.mimecast.com/s/vFbQCRg2XU46yGJc95bum?domain=equitydevelopment.co.uk)
Enquiries
For further information, please contact:
Benchmark Holdings plc benchmark@mphc.com
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations
Deutsche Numis (Broker and NOMAD) Tel: 020 7260 1000
Freddie Barnfield, Duncan Monteith, Sher Shah
MHP Communications Tel: +44(0) 20 3128 8100 / (0)7884 494112
Katie Hunt, Reg
Hoare
benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)
About Benchmark
Benchmark is a market leading aquaculture biotechnology company. Benchmark's
mission is to drive sustainability in aquaculture by delivering products and
solutions in genetics, advanced nutrition and health which improve yield,
growth and animal health and welfare.
Through a global footprint in 26 countries and a broad portfolio of products
and solutions, Benchmark addresses many of the major aquaculture species -
salmon, shrimp, sea bass and sea bream, and tilapia - in all the major
aquaculture regions around the world. Find out more at www.benchmarkplc.com.
Management Report
Benchmark's Q1 FY24 top line performance was relatively soft against a strong
Q1 FY23 but ahead of the previous quarter, maintaining momentum in the
business. The two largest business areas, Genetics and Advanced Nutrition
performed in line with management's expectations, while our Health business
area was affected by biological challenges faced by certain customers' fish
stock which led to the cancellation of orders for Ectosan® Vet and
CleanTreat® in December and therefore lower sales than previously
anticipated. As a result, Group revenues against the same period in FY23
were down 26% to £40.5m, 19% at a constant exchange rate (CER) but 11% ahead
of Q4 FY23. Lower revenues against the same period last year also reflect a
strong comparative quarter in FY23 which benefitted from shortage in supply of
salmon eggs in the market. Gross profit margin for the Group was 45% in line
with the previous year (Q1 FY23: 45%).
Adjusted EBITDA margin excluding fair value movements from biological assets
was 18% (Q1 FY23: 23%) with an improvement in Genetics and Advanced Nutrition
offset by Health. Excluding Health, the Adj. EBITDA margin for the Group
excluding fair value movements was 20% (Q1 FY23: 19%). Adjusted EBITDA from
excluding fair value movements from biological assets was £7.5m (Q1 FY23:
£12.5m). Again, the Group suffered adverse foreign exchange conditions, and
at CER Adj. EBITDA excluding fair value movements fell 34%.
The Group has maintained financial discipline with a focus on spend and
profitability. As a result, despite inflationary pressure, operating costs
were £10.5m, 9% below the prior year (6% at CER). R&D costs were £1.5m,
broadly in line with Q1 FY23 (Q1 FY23: £1.6m). Total R&D investment
including capitalised development costs was £1.6m, in line with the prior
year (Q1 FY23: £1.6m).
Depreciation and amortisation increased marginally from the comparative period
last year to £10.5m (Q1 FY23: £10.0m). The increase in depreciation arising
from the demobilisation of one of the CleanTreat® vessels was offset by a
reduction in amortisation as some acquired assets become fully written off.
Exceptional costs incurred in the period of £0.5m (Q1 FY23: £1.0m) related
to costs associated with business reorganisation and the closure of the
tilapia business.
Net finance cost in the period was £2.8m; (Q1 FY23: £0.2m income) with the
increase primarily explained by a £2.5m credit in Q1 FY23 from changes the
fair value of derivative financial instruments. In addition, there was an
increase in interest costs in the year of £0.3m resulting from higher
borrowings in the current quarter.
The Group reported a loss before tax of £7.2m (Q1 FY23: profit before tax
£0.6m); the loss after tax for the period was £7.6m (Q1 FY23: loss after tax
£0.7m).
Net operating cash outflow from operating activities for the period was £5.6m
(Q1 FY23: inflow £8.1m) impacted by the lower sales. However, this also
included an increase in net working capital of £10.8m against a much lower of
£0.8m in the Q1 FY23, with the main movements being a lower reduction in
receivables and biological assets and a higher reduction in payables in Q1 24
than in the comparative quarter. Movements in biological assets and
receivables both showed larger reductions in Q1 23 than in Q1 24 and were
dominated by the impact in Genetics of the supply issues in the market in Q4
FY22 and Q1 FY23. The opportunities from which Benchmark was able to benefit
due to these supply issues meant an abnormally high biological asset inventory
in September 2022, and hence a larger reduction in Q1 FY23, during which the
supply issues were resolved, than in Q1 FY24 when inventory levels were more
normalised throughout. The same supply issues also meant a higher level of
debtors in September 2022 from higher sales in Q4 FY22 leading to a larger
reduction in debtors in Q1 23 than in Q1 24. The large reduction in
creditors in Q1 24 compared to Q1 23 occurred due to larger contractual
payments for artemia supplies in Q1 24, an increase in payables for
exceptional costs within Corporate for the Oslo listing preparation work at
the end of Q1 23 which were paid off after the end of that quarter and higher
accrued harvest production costs at September 2023 which returned to normal
levels at the end of Q1 24.
Net cash used in investing activities was significantly reduced to £0.8m (Q1
FY23: £2.2m) of which capex was £1.0m (Q1 FY23: £1.9m). Capex in the
period related to investment in Genetics (£0.6m) and Advanced Nutrition
(£0.3m). Net cash outflow from financing activities was £5.5m arising
mainly from interest and lease payments. Net decrease in cash in the quarter
was £11.8m (Q1 FY23: £8.1m inflow) to leave the period end cash position at
£24.2m and liquidity of £36.4m.
Advanced Nutrition
Advanced Nutrition revenues were £19.3m, 15% below the prior year (-7% CER)
but 13% ahead of Q4 FY23, a good performance against a backdrop of continuing
soft market conditions. By geography performance was stronger in Europe driven
by sales to the marine fish market, and in the Americas, while Asia was most
affected by conditions in the shrimp markets. Innovation continues to be an
important part of the Group's strategy and we were pleased with the customer
reception for the recently launched SnappArt, with initial volumes sold out.
Gross margin was 53% (Q1 FY23: 50%) reflecting a change in product mix. Q1
FY24 Adjusted EBITDA was £4.6m (Q1 FY23: £5.3m) as a result of lower sales.
Adjusted EBITDA margin was marginally up at 24% (Q1 FY23: 23%).
The resilience and continued good performance of Advanced Nutrition in
difficult markets reflects our continuous innovation, focused commercial
effort, financial discipline, and our drive to improve operational
efficiency. Together this puts the business in a strong position for a
recovery in the market.
Genetics
Genetics delivered revenues of £15.2m in Q1 FY24 (Q1 FY23: £21.4m) primarily
driven by normalised egg volumes against the prior year which benefitted from
supply constraints in the market. Egg sales were 86m against 118m in Q1
FY23. Our core salmon business had revenues of £13.6m (Q1 FY23: £20.7m)
primarily driven by lower egg sales and lower harvest income at £2.8m (Q1
FY23: £3.5m). Revenues from genetic services were 15% ahead of the prior
year.
In our growth vectors, increasing commercial traction in Chile translated into
revenues of £0.9m (Q1 FY23: £0.01m) taking the Company closer to
profitability. Sales of shrimp genetics were broadly in line with the prior
year at £0.3m (Q1 FY23: £0.3m).
Adjusted EBITDA for Q1 FY24 excluding fair value movements of biological
assets was £3.3m, 19% below the prior year (Q1 FY23: £4.1m), and at constant
exchange rates, was 9% below the prior year. The fair value movements on
biological assets in the quarter was a £0.8m reduction in value (Q1 FY23:
£1.2m reduction), so Adjusted EBITDA including fair value movements for Q1
FY24 was £2.5m (Q1 FY23: £2.9m). Adjusted EBITDA margin excluding fair value
movements in biological assets increased to 22% (Q1 FY23: 19%) reflecting an
improvement in our growth vectors, Chile and shrimp genetics.
Innovation is a key element in the strategy of our core genetics business to
bring in new traits and technologies that differentiate our offering and can
add substantial value for our customers. We continue to progress our work on
sterility and gene editing to position ourselves at the forefront of these
developments. In addition, post year end we launched a new product portfolio
of specialised, premium genetics products based on innovation in our existing
technologies, including genomics and cryopreservation, to optimise our genetic
design, and focus our selection intensity on the traits that give the most
benefit to customers.
Post period end, the Company reported an isolated incident of ISA virus
(Infectious Salmon Anaemia) at its facility in Salten. The tank containing the
affected fish is an isolated unit with separate water systems and farming
equipment. The tank contained 1,582 broodstock fish, equivalent to a
production of 12m salmon eggs. All fish in the tank were culled and the
Company does not expect the incident to impact its delivery capability. The
Company has accessible broodstock from other fish groups in the facility as
well as access to additional supply of eggs from third party partners in
Norway and from its own facility in Iceland.
Health
Revenues in Q1 FY24 were £6.1m (Q1 FY23: £10.4m) primarily reflecting
lower sales of Ectosan® Vet and CleanTreat® which were impacted by
biological challenges at certain customers which led to the cancellation of
sales in December. Revenues from Ectosan® Vet and CleanTreat® were £4.0m
of which £1.4m was derived from recharging vessel and fuel costs associated
with the Ectosan® Vet and CleanTreat® operations. Sales of Salmosan® Vet
- the Group's well-established sea lice treatment were down as a result of
geographic mix with sales skewed towards countries with lower pricing versus
last year. The reduction in revenues resulted in Adjusted EBITDA of £0.6m
in the quarter (Q1 FY23: £4.1m).
In December 2023, we took the decision to demobilise one of the two
CleanTreat® vessels in light of the low-capacity utilisation. The decision
also led to a streamlining of the Health business area reducing its costs
base. As Q2 evolves we will monitor capacity utilisation, prioritising cash
management in the transition period until new a less capital intensive
business model is in place. We view a model with CleanTreat® integrated
into wellboats as the medium to long term solution and continue our work to
bring this into place. In addition, we are exploring a third configuration for
CleanTreat® based on a barge in order to provide customers with continuity
through a less costly alternative until the wellboat solution is implemented.
Strategic Review
On 22 January, the Company announced a strategic review to evaluate the
Company's options including, but not limited to, a potential sale of the
Company as a whole or of one or more individual business units. The purpose of
the strategic review is to establish whether there are bidders prepared to
offer a price that the Board considers attractive relative to its view of the
Company's intrinsic value. Further announcements will be made as appropriate
in due course.
Current Trading and Outlook
The Group is trading in line with management's expectations for the full year
underpinned by good visibility of revenues in Genetics, continued good
performance in Advanced Nutrition and streamlining of our infrastructure and
operations in Health. Post period end the Genetics and Advanced Nutrition
business areas are trading well, and actions are being taken to manage costs
and cash in our Health business area through the period of transition to a new
business model.
All figures in £000's Notes Q1 2024 Q1 2023 FY 2023
(unaudited)
Restated*
(audited)
(unaudited)
Revenue 4 40,473 54,422 169,476
Cost of sales (22,110) (30,024) (82,726)
Gross profit 18,363 24,398 86,750
Research and development costs (1,517) (1,551) (6,069)
Other operating costs (10,490) (11,568) (45,157)
Share of profit/(loss) of equity-accounted investees, net of tax 318 56 (32)
Adjusted EBITDA² 6,674 11,335 35,492
Exceptional - restructuring, acquisition and disposal related items 6 (517) (972) (3,904)
EBITDA¹ 6,157 10,363 31,588
Depreciation and impairment (6,249) (4,539) (18,409)
Amortisation and impairment (4,268) (5,502) (18,495)
Operating (loss)/profit (4,360) 322 (5,316)
Finance cost 7 (5,385) (7,277) (15,048)
Finance income 7 2,554 7,508 7,670
(Loss)/profit before taxation (7,191) 553 (12,694)
Tax on loss/profit 8 (433) (779) (3,365)
Loss from continuing operations (7,624) (226) (16,059)
Discontinued operations
Loss from discontinued operations, net of tax 5 - (453) (5,505)
(7,624) (679) (21,564)
Loss for the year attributable to:
- Owners of the parent (7,627) (1,283) (23,146)
- Non-controlling interest 3 604 1,582
(7,624) (679) (21,564)
Earnings per share
Basic loss per share (pence) 9 (1.03) (0.18) (3.16)
Diluted loss per share (pence) 9 (1.03) (0.18) (3.16)
Earnings per share - continuing operations
Basic loss per share (pence) 9 (1.03) (0.12) (2.41)
Diluted loss per share (pence) 9 (1.03) (0.12) (2.41)
Adjusted EBITDA from continuing operations 6,674 11,335 35,492
Adjusted EBITDA from discontinued operations - (368) (1,254)
Total Adjusted EBITDA 6,674 10,967 34,238
1 EBITDA - Earnings before interest, tax, depreciation, amortisation, and
impairment
2 Adjusted EBITDA - EBITDA before exceptional items including acquisition
related items
* Q1 2023 numbers have been restated to reflect certain operations of the
Group that have been classified as discontinued operations during the
period in line with IFRS 5. (See Note 5).
All figures in £000's Q1 2024 Q1 2023 FY 2023
(unaudited)
Restated
(audited)
(unaudited)
Loss for the period (7,624) (679) (21,564)
Other comprehensive income
Items that are or may be reclassified subsequently to profit or loss
Foreign exchange translation differences (7,413) (18,040) (23,475)
Cash flow hedges - changes in fair value (890) (516) (2,123)
Cash flow hedges - reclassified to profit or loss 120 (113) 2,623
Total comprehensive income for the period (15,807) (19,348) (44,539)
Total comprehensive income for the period attributable to:
- Owners of the parent (15,741) (19,751) (45,404)
- Non-controlling interest (66) 403 865
(15,807) (19,348) (44,539)
Total comprehensive income for the period attributable to owners of the
parent:
- Continuing operations (15,741) (19,547) (39,777)
- Discontinued operations* - (204) (5,627)
(15,741) (19,751) (45,404)
* Total comprehensive income for the period relating to discontinued
operations for Q1 2024 includes the loss of £Nil (Q1 2023: £453,000) and
foreign exchange gain of £Nil (Q1 2023: £249,000). FY23 includes the loss of
£5,505,000 and foreign exchange loss of £122,000.
The accompanying notes are an integral part of this consolidated financial
information.
31 December 2023 31 December 2022 30 September 2023
All figures in £000's Notes (unaudited) (unaudited) (audited)
Assets
Property, plant and equipment 71,664 80,505 73,411
Right-of-use assets 16,513 23,883 19,804
Intangible assets 194,953 224,606 206,077
Equity-accounted investees 3,780 3,041 3,558
Other investments 1 15 14
Biological and agricultural assets 23,779 24,930 18,406
Trade and other receivables - 422 -
Non-current assets 310,690 357,402 321,270
Inventories 24,505 28,222 25,269
Biological and agricultural assets 19,926 17,154 27,586
Trade and other receivables 56,380 51,159 59,795
Cash and cash equivalents 24,164 42,782 36,525
124,975 139,317 149,175
Assets held for sale 10 500 - 850
Current assets 125,475 139,317 150,025
Total assets 436,165 496,719 471,295
Liabilities
Trade and other payables (33,513) (35,254) (47,329)
Loans and borrowings 11 (18,682) (16,227) (20,045)
Corporation tax liability (5,929) (10,349) (6,422)
Provisions (2,410) (1,587) (1,280)
Current liabilities (60,534) (63,417) (75,076)
Loans and borrowings 11 (80,032) (87,958) (81,954)
Other payables (5,930) (4,369) (6,842)
Deferred tax (22,168) (25,105) (24,106)
Provisions (440) - (700)
Non-current liabilities (108,570) (117,432) (113,602)
Total liabilities (169,104) (180,849) (188,678)
Net assets 267,061 315,870 282,617
Issued capital and reserves attributable to owners of the parent
Share capital 12 739 739 739
Additional paid-in share capital 12 37,428 432,423 37,428
Capital redemption reserve 5 5 5
Retained earnings 176,114 (186,120) 183,489
Hedging reserve (973) (1,332) (203)
Foreign exchange reserve 47,603 59,866 54,947
Equity attributable to owners of the parent 260,916 305,581 276,405
Non-controlling interest 6,146 10,289 6,212
Total equity and reserves 267,062 315,870 282,617
The accompanying notes are an integral part of this consolidated financial
information
Share Additional paid-in share capital Other Hedging Retained Total attributable Non- Total
capital
reserves*
reserve
earnings
to equity holders of
controlling
equity
parent
interest
£000 £000 £000 £000 £000 £000 £000 £000
As at 1 October 2023 (audited) 739 37,428 54,952 (203) 183,489 276,405 6,212 282,617
Comprehensive income/(loss) for the period
Profit/(loss) for the period - - - - (7,627) (7,627) 3 (7,624)
Other comprehensive income/(loss) - - (7,344) (770) - (8,114) (69) (8,183)
Total comprehensive income/(loss) for the period - - (7,344) (770) (7,627) (15,741) (66) (15,807)
Contributions by and distributions to owners
Share-based payment - - - - 252 252 - 252
Total contributions by and distributions to owners - - - - 252 252 - 252
Total transactions with owners of the Company - - - - 252 252 - 252
As at 31 December 2023 (unaudited) 739 37,428 47,608 (973) 176,114 260,916 6,146 267,062
As at 1 October 2022 (audited) 704 420,824 77,710 (703) (185,136) 313,399 9,886 323,285
Comprehensive income/(loss)for the period
Profit/(loss) for the period - - - - (1,283) (1,283) 604 (679)
Other comprehensive income/(loss) - - (17,839) (629) - (18,468) (201) (18,669)
Total comprehensive income/(loss)for the period - - (17,839) (629) (1,283) (19,751) 403 (19,348)
Contributions by and distributions to owners
Share issue 35 12,985 - - - 13,020 - 13,020
Share issue costs recognised through equity - (1,386) - - - (1,386) - (1,386)
Share-based payment - - - - 299 299 - 299
Total contributions by and distributions to owners 35 11,599 - - 299 11,933 - 11,933
Total transactions with owners of the Company 35 11,599 - - 299 11,933 - 11,933
As at 31 December 2022 (unaudited) 739 432,423 59,871 (1,332) (186,120) 305,581 10,289 315,870
As at 1 October 2022 (audited) 704 420,824 77,710 (703) (185,136) 313,399 9,886 323,285
Comprehensive income/(loss) for the period
Profit/(loss) for the period - - - - (23,146) (23,146) 1,582 (21,564)
Other comprehensive income/(loss) - - (22,758) 500 - (22,258) (717) (22,975)
Total comprehensive income/(loss) for the period - - (22,758) 500 (23,146) (45,404) 865 (44,539)
Contributions by and distributions to owners
Share issue 35 12,985 - - - 13,020 - 13,020
Share issue costs recognised through equity - (2,146) - - - (2,146) - (2,146)
Cancellation of part of share premium account - (394,235) - - 394,235 - - -
Share-based payment - - - - 1,006 1,006 - 1,006
Total contributions by and distributions to owners 35 (383,396) - - 395,241 11,880 - 11,880
Changes in ownership
Acquisition of NCI - - - - (3,470) (3,470) (4,539) (8,009)
Total changes in ownership interests - - - - (3,470) (3,470) (4,539) (8,009)
Total transactions with owners of the Company 35 (383,396) - - 391,771 8,410 (4,539) 3,871
As at 30 September 2023 (audited) 739 37,428 54,952 (203) 183,489 276,405 6,212 282,617
*Other reserves in this statement is an aggregation of capital redemption
reserve and foreign exchange reserve
Q1 2024 Q1 2023 FY 2023
Notes (unaudited) (unaudited) (audited)
Cash flows from operating activities
Loss for the period (7,624) (679) (21,564)
Adjustments for:
Depreciation and impairment of property, plant and equipment 2,969 2,033 8,453
Depreciation and impairment of right-of-use assets 3,280 2,582 10,260
Amortisation and impairment of intangible fixed assets 4,268 5,502 18,495
(Profit)/loss on sale of property, plant and equipment 5 (37) (121)
Loss on sale of discontinued operation - - 3,774
Finance income (210) (7,508) (2,802)
Finance costs 2,685 7,010 10,535
Loss on disposal of investments in joint ventures (42) - -
Share of (profit)/loss of equity-accounted investees, net of tax (318) (56) 32
Foreign exchange gains 745 418 (1,814)
Share-based payment expense 252 299 1,005
Tax expense 433 779 3,365
Decrease/(increase) in trade and other receivables 1,191 4,011 (6,570)
Decrease/(increase) in inventories 570 1,571 2,877
Decrease/(increase) in biological and agricultural assets 813 3,294 (1,659)
(Decrease)/Increase in trade and other payables (13,393) (9,633) 3,909
Decrease /(increase) in provisions 7 (9) 386
(4,369) 9,577 28,561
Income taxes paid (1,204) (1,509) (8,556)
Net cash flows generated from operating activities (5,573) 8,068 20,005
Investing activities
Acquisition of subsidiaries - - (48)
Purchase of investments in associates - (63) (558)
Receipts from disposal of subsidiaries, joint ventures, and other investments 37 - 1,250
Purchases of property, plant and equipment (921) (1,829) (5,953)
Purchase of intangibles (50) (30) (196)
Capitalised research and development costs (62) (54) (632)
Cash advances and loans made to other parties - (415) -
Proceeds from sale of fixed assets 18 75 227
Cash receipts from swap contracts - - 11
Interest received 204 160 627
Net cash flows used in investing activities (774) (2,156) (5,272)
Financing activities
Proceeds of share issues - 13,020 13,020
Share-issue costs recognised through equity - (1,386) (2,146)
Acquisition of minority interests in subsidiaries, net of cash acquired - - (8,009)
Proceeds from bank or other borrowings, net of borrowing fees - (600) 21,847
Repayment of bank or other borrowings (386) (4,397) (18,470)
Interest and finance charges paid (2,250) (2,211) (9,131)
Repayments of lease liabilities (2,854) (2,200) (9,438)
Net cash used in financing activities (5,490) 2,226 (12,327)
Net increase/(decrease) in cash and cash equivalents (11,837) 8,138 2,406
Cash and cash equivalents at beginning of period 36,525 36,399 36,399
Effect of movements in exchange rate (524) (1,755) (2,280)
Cash and cash equivalents at end of period 24,164 42,782 36,525
1. Basis of preparation
Benchmark Holdings plc (the 'Company') is a company incorporated and domiciled
in the United Kingdom. These consolidated quarterly financial statements as at
and for the three months ended 31 December 2023 comprises those of the Company
and its subsidiaries (together referred to as the 'Group').
These consolidated quarterly financial statements do not comprise statutory
accounts within the meaning of section 434 of the Companies Act 2006 and are
unaudited. These financial statements do not include all the information
required for a complete set of IFRS financial statements. However, selected
explanatory notes are included to explain events and transactions that are
significant to an understanding of the changes in the Group's financial
position and performance since the last annual financial statements. The
Group's last annual statutory financial statements as at and for the year
ended 30 September 2023 were prepared in accordance with (i) UK-adopted
International Accounting Standards and (ii) IFRS adopted pursuant to
Regulation (EC) No. 1606/2002 as it applied in the European Union ("Adopted
IFRS") and are available from the Company's website at www.benchmarkplc.com
(http://www.benchmarkplc.com) .
The prior year comparatives are derived from audited financial information for
Benchmark Holdings PLC Group as set out in the Annual Report and Accounts for
the year ended 30 September 2023 and the unaudited financial information in
the Quarterly Financial Report for the three months ended 31 December 2022.
The comparative figures for the financial year ended 30 September 2023 are not
the Company's statutory accounts for that financial year. Those accounts were
approved by the Directors on 29 November 2023 and have been delivered to the
Registrar of Companies. The audit report received on those accounts was (i)
unqualified and (ii) did not contain a statement under section 498(2) or (3)
of the Companies Act 2006.
Statement of Compliance
These consolidated quarterly financial statements have been prepared and
approved by the Directors in accordance with UK and EU adopted IAS 34 'Interim
Financial Reporting'. These financial statements do not include all of the
information required for the full annual financial statements and should be
read in conjunction with the Group's last annual consolidated financial
statements as at and for the year ended 30 September 2023. These consolidated
quarterly financial statements were approved by the Board of Directors on
15 February 2024.
Going concern
The Group's business activities, together with the factors likely to affect
its future development, performance and position are set out in the Management
Report.
As at 31 December 2023 the Group had net assets of £267.1m (30 September
2023: £282.6m), including cash of £24.2m (30 September 2022: £36.5m) as set
out in the consolidated balance sheet. The Group made a loss for the period of
£7.6m (year ended 30 September 2023: loss £21.6m).
As noted in the Management Report, the business experienced tough market
conditions in the shrimp markets in FY23 which continued into the first
quarter of FY24. This has also combined with lower demand for its sealice
solution in the first quarter of FY24. The lower demand has resulted in the
decision to reduced available CleanTreat® capacity in the market to match
demand and preserve cash as we move towards a lower cost CleanTreat® model.
The Directors have reviewed forecasts and cash flow projections for a period
of at least 12 months including downside sensitivity assumptions in relation
to trading performance across the Group to assess the impact on the Group's
trading and cash flow forecasts and on the forecast compliance with the
covenants included within the Group's financing arrangements.
In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan®Vet and CleanTreat® offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reductions in
expected biomass treated and reduction in short-term treatment capacity. Key
downside sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth in Chile and
removal of an additional financing opportunity within Genetics, along with
sensitivities on sales growth in revenues and pressure on pricing on CIS
artemia in Advanced Nutrition. Mitigating measures within the control of
management have been identified should they be required in response to these
sensitivities, including reductions in areas of discretionary spend, tight
control over new hires, deferral of capital projects and temporary hold on
R&D for non-imminent products.
The Directors consider that adequate finance facilities are in place following
the completion of the refinancing in FY23, and with financial instruments in
place to fix interest rates and opportunities available to mitigate globally
high inflation rates, the Group continues to show resilience against current
global economic pressures.
The Board believes that the current share price materially undervalues the
combined value of Benchmark's businesses and the long-term prospects of the
Company. Consequently, the Board announced on 22 January 2024 the decision to
undertake a formal review of the Company's strategic options, which include a
potential sale of the Company as a whole or of one or more of the individual
business units. As this is only the very beginning of the process, there are
currently no deal or deals identified or underway and all parts of the
business are operating as usual, so there is no impact on the Directors'
assessment of going concern.
The Directors are therefore confident that even under all of the above
sensitivity analysis and ongoing strategic review, the Group has sufficient
liquidity and resources throughout the period under review whilst still
maintaining adequate headroom against the borrowing covenants. They therefore
remain confident that the Group has adequate resources to continue to meet its
liabilities as and when they fall due within the period of 12 months from the
date of approval of these financial statements. Based on their assessment, the
Directors believe it remains appropriate to prepare the financial statements
on a going concern basis.
2. Accounting policies
The accounting policies adopted are consistent with those used in preparing
the consolidated financial statements for the financial year ended 30
September 2023.
Taxes on income in the interim periods are accrued using the tax rate that
would be applicable to expected total earnings.
Alternative performance measures ('APMs')
The Directors measure the performance of the Group based on a range of
financial measures, including measures not recognised by UK or EU-adopted
IFRS. These APMs may not be directly comparable with other companies' APMs,
and the Directors do not intend these as a substitute for, or superior to,
IFRS measures.
Directors have presented the performance measures Adjusted EBITDA, Adjusted
Operating Profit, Adjusted Profit Before Tax and Adjusted EBITDA excluding
fair value movement on biological assets because they monitor performance at a
consolidated level using these and believe that these measures are relevant to
an understanding of the Group's financial performance (see note 13).
Furthermore, the Directors also refer to current period results using constant
currency, which are derived by retranslating current period results using the
prior year's foreign exchange rates.
Use of estimates and judgements
The preparation of quarterly financial information requires management to make
certain judgements, estimates and assumptions that affect the application of
accounting policies and the reported amounts of assets and liabilities, income
and expense. Actual amounts may differ from these estimates.
In preparing these quarterly financial statements the significant judgements
made by management in applying the Group's accounting policies and the key
sources of estimation uncertainty were the same as those applied to the
consolidated financial statements for the year ended 30 September 2023.
3. Segment information
Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.
The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:
· Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova.
· Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.
· Health - the segment provides health products and services to the
global aquaculture market.
In order to reconcile the segmental analysis to the consolidated income
statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.
Measurement of operating segment profit or loss
Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities. This policy
was applied consistently throughout the current and prior period.
3. Segment information (continued)
Reconciliations of segmental information to IFRS measures
Segmental Revenue
All figures in £000's Q1 2024 Q1 2023 FY 2023
(unaudited)
(unaudited)*
(audited)*
Genetics 15,164 21,439 65,791
Advanced Nutrition 19,283 22,680 78,503
Health 6,059 10,385 25,514
Corporate 1,349 1,437 5,747
Inter-segment sales (1,382) (1,446) (5,811)
Total 40,473 54,495 169,744
Segmental Adjusted EBITDA
All figures in £000's Q1 2024 Q1 2023 FY 2023
(unaudited)
(unaudited)*
(audited)*
Genetics 2,498 2,563 14,409
Advanced Nutrition 4,600 5,297 18,374
Health 570 4,067 4,772
Corporate (994) (960) (3,317)
Total 6,674 10,967 34,238
Reconciliation of Reportable Segments Adjusted EBITDA to Loss before
taxation
All figures in £000's Q1 2024 Q1 2023 FY 2023
(unaudited)
(unaudited)*
(audited)*
Total reportable segment Adjusted EBITDA 7,668 11,927 37,555
Corporate Adjusted EBITDA (994) (960) (3,317)
Adjusted EBITDA 6,674 10,967 34,238
Exceptional - restructuring, acquisition and disposal related items (517) (972) (7,817)
Depreciation and impairment (6,249) (4,615) (18,713)
Amortisation and impairment (4,268) (5,502) (18,495)
Net finance costs (2,831) 222 (7,412)
Loss before taxation from continuing operations (7,191) 100 (18,199)
Reconciliation of segmental information to IFRS measures - Revenue and Loss
before tax
Revenue
Q1 2024 Q1 2023 FY 2023
(unaudited)
Restated
(audited)
(unaudited)
Total revenue per segmental information 40,473 54,495 169,744
Less: revenue from discontinued operations - (73) (268)
Consolidated revenue 40,473 54,422 169,476
Loss before tax
Q1 2024 Q1 2023 FY 2023
(unaudited)
Restated
(audited)
(unaudited)
Profit/(loss) before tax per segmental information (7,191) 100 (18,199)
Less: (profit)/loss before tax from discontinued operations - 453 5,505
Consolidated Profit/(loss) before tax (7,191) 553 (12,694)
* Results include discontinued operations, see note 5 for further detail
4. Revenue
The Group's operations and main revenue streams are those described in its
financial statements to 30 September 2023. The Group's revenue is derived from
contracts with customers.
Disaggregation of revenue
In the following tables, revenue is disaggregated by primary geographical
market and by sales of goods and services. The table includes a reconciliation
of the disaggregated revenue with the Group's reportable segments (see note
3).
Sale of goods and provision of services
3 months ended 31 December 2023 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Sale of goods 14,841 19,254 4,459 - - 38,554 - 38,554
Provision of services 319 - 1,600 - - 1,919 - 1,919
Inter-segment sales 4 29 - 1,349 (1,382) - - -
15,164 19,283 6,059 1,349 (1,382) 40,473 - 40,473
3 months ended 31 December 2022 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Sale of goods 21,121 22,672 7,449 - - 51,242 73 51,169
Provision of services 317 - 2,936 - - 3,253 - 3,253
Inter-segment sales 1 8 - 1,437 (1,446) - - -
21,439 22,680 10,385 1,437 (1,446) 54,495 73 54,422
12 months ended 30 September 2023 (audited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Sale of goods 61,372 78,449 17,707 - - 157,528 268 157,260
Provision of services 4,409 - 7,807 - - 12,216 - 12,216
Inter-segment sales 10 54 - 5,747 (5,811) - - -
65,791 78,503 25,514 5,747 (5,811) 169,744 268 169,476
4. Revenue (continued)
Primary geographical markets
3 months ended 31 December 2023 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Norway 9,557 311 4,809 - - 14,677 - 14,677
Vietnam - 1,635 - - - 1,635 - 1,635
India - 4,163 - - - 4,163 - 4,163
Iceland 1,233 - - - - 1,233 - 1,233
Ecuador 32 1,489 - - - 1,521 - 1,521
Canada 60 22 142 - - 224 - 224
Turkey 9 1,898 - - - 1,907 - 1,907
Indonesia 92 1,282 - - - 1,374 - 1,374
Faroe Islands 1,472 - 432 - - 1,904 - 1,904
Greece - 1,948 - - - 1,948 - 1,948
China 98 502 - - - 600 - 600
United Kingdom 774 7 53 - - 834 - 834
Chile 984 - 623 - - 1,607 - 1,607
Rest of Europe 382 1,656 - - - 2,038 - 2,038
Rest of World 467 4,341 - - - 4,808 - 4,808
Inter-segment sales 4 29 - 1,349 (1,382) - - -
15,164 19,283 6,059 1,349 (1,382) 40,473 - 40,473
3 months ended 31 December 2022 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Norway 16,884 90 8,295 - - 25,269 - 25,269
Vietnam - 2,718 - - - 2,718 - 2,718
India - 4,203 - - - 4,203 - 4,203
Iceland 1,788 - - - - 1,788 - 1,788
Ecuador 20 1,740 - - - 1,760 - 1,760
Canada 25 21 1,565 - - 1,611 - 1,611
Turkey 6 2,204 - - - 2,210 - 2,210
Indonesia 208 1,691 - - - 1,899 - 1,899
Faroe Islands 1,095 - 229 - - 1,324 - 1,324
Greece - 2,269 - - - 2,269 - 2,269
China - 1,836 - - - 1,836 - 1,836
United Kingdom 737 19 42 - - 798 - 798
Chile 12 2 254 - - 268 - 268
Rest of Europe 274 1,622 - - - 1,896 - 1,896
Rest of World 389 4,257 - - - 4,646 73 4,573
Inter-segment sales 1 8 - 1,437 (1,446) - - -
21,439 22,680 10,385 1,437 (1,446) 54,495 73 54,422
4. Revenue (continued)
Primary geographical markets (continued)
12 months ended 30 September 2023 (audited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total Discontinued Continuing
Norway 39,008 899 19,596 - - 59,503 - 59,503
Vietnam - 11,087 - - - 11,087 - 11,087
India - 9,743 - - - 9,743 - 9,743
Iceland 7,343 - - - - 7,343 - 7,343
Ecuador 38 7,257 - - - 7,295 - 7,295
Canada 3,071 96 4,032 - - 7,199 - 7,199
Turkey 93 7,009 - - - 7,102 - 7,102
Indonesia 637 4,099 - - - 4,736 - 4,736
Faroe Islands 6,160 - 718 - - 6,878 - 6,878
Greece - 6,759 - - - 6,759 - 6,759
China 327 4,502 - - - 4,829 - 4,829
United Kingdom 3,957 85 177 - - 4,219 - 4,219
Chile 1,824 12 991 - - 2,827 - 2,827
Rest of Europe 1,470 4,879 - - - 6,349 - 6,349
Rest of World 1,853 22,022 - - - 23,875 268 23,607
Inter-segment sales 10 54 - 5,747 (5,811) - - -
65,791 78,503 25,514 5,747 (5,811) 169,744 268 169,476
5. Discontinued activities
During FY23, the group divested its tilapia business for consideration of USD
1 in a management buy out. Consequently, these operations were classified as
discontinued in the prior year and a restatement of the consolidated income
statement for the period ended 31 December 2022 has been made to reflect
these changes.
Summary of restatement of Q1 FY23 results as reported in Q1 FY24 financial
statements
Continuing operations Discontinued operations
All figures in £000's Revenue Adjusted EBITDA Loss from continuing operations Loss from discontinued operations
As stated in Q1 FY23 financial statements 54,495 10,967 (679) -
Reclassified in Q1 (73) 368 453 (453)
As stated in Q1 FY24 financial statements 54,422 11,335 (226) (453)
Results from discontinued operations
Q1 FY23
Q1 FY24 Restated FY23
£000 £000 £000
Revenue - 73 268
Cost of sales - (244) (973)
Gross profit - (171) (705)
Research and development costs - (12) (59)
Other operating costs - (185) (490)
Share of profit of equity-accounted investees, net of tax - - -
Adjusted EBITDA - (368) (1,254)
Exceptional loss on disposal - - (3,913)
EBITDA - (368) (5,167)
Depreciation and impairment - (76) (304)
Amortisation and impairment - - -
Operating loss / Loss before taxation - (444) (5,471)
Net finance costs - (9) (34)
Loss before taxation - (453) (5,505)
Tax on loss - - -
Loss from discontinued operations - (453) (5,505)
Exceptional items within discontinued operations
Q1 FY24 Q1 FY23 FY23
£000 £000 £000
Profit/(loss) on disposal of subsidiaries - - 3,774
Profit/(loss) on other asset disposals - - 139
Total exceptional recognised - - 3,913
Results from discontinued operations by segment
The results from discontinued operations relate solely to the Genetics
operating segment.
6. Exceptional - restructuring/acquisition and disposal related items
Items that are material because of their size or nature, non-recurring and
whose significance is sufficient to warrant separate disclosure and
identification within the consolidated financial statements are referred to as
exceptional items. The separate reporting of exceptional items helps to
provide an understanding of the Group's underlying performance.
All figures in £000's Q1 2024 Q1 2023 FY 2023
(unaudited)
(unaudited)
(audited)
Acquisition related items - - 652
Exceptional restructuring costs 517 948 3,470
Disposal related items - 24 (218)
Total exceptional items 517 972 3,904
In FY2023 acquisition related items comprise fees incurred in the year in
connection with an aborted acquisition.
Exceptional costs include: £517,000 of restructuring costs (Q1 2023:
£85,000, FY2023 £872,000). In addition to this in FY23 there were
£2,598,000 (Q1 2023: £863,000) of legal and professional costs in relation
to preparing for listing the Group on the Oslo stock exchange.
Disposal related items of £nil relation to disposals (Q1 2023: £24,000,
FY2023 £17,000). In FY2023 there was also a credit of £235,000 for
additional contingent consideration received and receivable relating to the
disposal of Improve International Limited and its subsidiaries on 23 June
2020.
7. Net finance costs
All figures in £000's Q1 2024 Q1 2023 FY 2023
(unaudited)
Restated
(audited)
(unaudited)
Interest received on bank deposits 210 160 627
Foreign exchange gains on financing activities - - 158
Foreign exchange gains on operating activities 2,344 4,825 4,709
Cash flow hedges - ineffective portion of changes in fair value - 2,523 2,176
Finance income 2,554 7,508 7,670
Leases (interest portion) (336) (345) (1,620)
Foreign exchange losses on operating activities (2,700) (4,922) (4,547)
Interest expense on financial liabilities measured at amortised cost (2,349) (2,010) (8,881)
Finance costs (5,385) (7,277) (15,048)
Net finance costs recognised in profit or loss (2,831) 231 (7,378)
8. Taxation
All figures in £000's Q1 2024 Q1 2023 FY 2023
(unaudited)
(unaudited)
(audited)
Analysis of charge in period
Current tax:
Current income tax expense on profits for the period 1,319 1,838 6,178
Adjustment in respect of prior periods - - (880)
Total current tax charge 1,319 1,838 5,298
Deferred tax:
Origination and reversal of temporary differences (886) (1,059) (1,933)
Deferred tax movements in respect of prior periods - - -
Total deferred tax charge/(credit) (886) (1,059) (1,933)
-
Total tax charge 433 779 3,365
9. Loss per share
Basic loss per share is calculated by dividing the loss attributable to
ordinary equity holders of the Company by the weighted average number of
ordinary shares in issue during the period.
Q1 2024 Q1 2023 FY 2023
(unaudited)
(unaudited)
(audited)
Loss attributable to equity holders of the parent (£000)
Continuing operations (7,627) (830) (17,641)
Discontinued operations - (453) (5,505)
Total (7,627) (1,283) (23,146)
Weighted average number of shares in issue (thousands) 739,352 710,087 731,935
Basic loss per share (pence)
Continuing operations (1.03) (0.12) (2.41)
Discontinued operations - (0.06) (0.75)
Total (1.03) (0.18) (3.16)
Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value (determined as the average market price of
the Company's shares for the period) based on the monetary value of the
subscription rights attached to outstanding share options and warrants. The
number of shares calculated above is compared with the number of shares that
would have been issued assuming the exercise of the share options and
warrants.
Therefore, the Company is required to adjust the earnings per share
calculation in relation to the share options that are in issue under the
Company's share-based incentive schemes, and outstanding warrants. However, as
any potential ordinary shares would be anti-dilutive due to losses being made
there is no difference between Basic loss per share and Diluted loss per share
for any of the periods being reported.
A total of 14,571,445 potential ordinary shares have not been included within
the calculation of statutory diluted loss per share for the year (30 September
2023: 8,948,132). These potential ordinary shares could dilute earnings/loss
per share in the future.
10. Assets held for sale
During 2022, management committed to sell certain property, plant and
equipment held within the Health business area. The property concerned is no
longer required by the business and the decision was made to sell. It is
anticipated that sale will take place within 12 months. The market value of
the property has fallen during the period and an impairment charge of
£350,000 has been incurred, such that the market value at the period end is
£500,000 (31 December 2023: £850,000).
There are no liabilities directly associated with the assets held for sale.
Assets held for sale Q1 2024 Q1 2023 FY 2023
(unaudited)
(unaudited)
(audited)
All figures in £000's
Property, plant and equipment 500 - 850
Total Assets held for sale 500 - 850
11. Loans and borrowings
Q1 2024 Q1 2023 FY 2023
(unaudited)
(unaudited)
(audited)
All figures in £000's
Non-Current
2025 750m NOK Loan notes 57,403 63,325 57,604
Bank borrowings 16,349 17,201 16,799
Unamortised debt issue costs (532) (1,459) (742)
Lease liabilities 6,812 8,891 8,293
80,032 87,958 81,954
Current
Bank borrowings 9,315 1,603 9,320
Unamortised debt issue costs (842) - (842)
Lease liabilities 10,209 14,624 11,567
18,682 16,227 20,045
Total loans and borrowings 98,714 104,185 101,999
The Group has an unsecured floating rate listed green bond of NOK 750m in
issue. The bond which matures in September 2025, has a coupon of three-month
NIBOR + 6.50% p.a. with quarterly interest payments, and is listed on the Oslo
Stock Exchange.
In FY 2023 on 21 November 2022, the Group refinanced its USD15m RCF, which was
provided by DNB Bank ASA (50%) and HSBC UK Bank PLC (50%), with a secured
GBP20m RCF provided by DNB Bank ASA, maturing on 27 June 2025. The margin on
this facility is a minimum of 2.75% and a maximum of 3.25%, dependent upon the
leverage of the Group above the relevant risk-free reference or IBOR rates
depending on which currency is drawn. At 31 December 2023 there was
£12,250,000 undrawn.
Additionally on 1 November 2022, the Group's Nordea Bank term loan of NOK
165.6m, which had a term loan of five years ending in November 2023 and
interest rate of 2.5% above three month NIBOR, was refinanced together with an
existing undrawn overdraft facility into a new loan facility of NOK 179.5m
with a new maturity date in a further five years no later than 15 January
2028. Other terms of this facility remain the same.
12. Share capital and additional paid-in share capital
Number Share Capital Additional paid-in
share capital
Allotted, called up and fully paid £000 £000
Ordinary shares of 0.1 pence each
Balance at 30 September 2023 and 31 December 2023 739,352,390 739 37,428
During the quarter ended 30 December 2023, the Group issued no new shares.
13. Alternative performance measures and other metrics
Management has presented the performance measures EBITDA, Adjusted EBITDA,
Adjusted EBITDA before fair value movement in biological assets, Adjusted
Operating Profit and Adjusted Profit Before Tax because it monitors
performance at a consolidated level using these and believes that these
measures are relevant to an understanding of the Group's financial
performance.
Adjusted EBITDA which reflects underlying profitability, is earnings before
interest, tax, depreciation, amortisation, impairment, and exceptional items
and is shown on the Income Statement.
Adjusted EBITDA before fair value movements in biological assets, which is
Adjusted EBITDA before the non-cash fair value movements in biological assets
arising from their revaluation in line with International Accounting
Standards.
Adjusted Operating Profit is operating loss before exceptional items and
amortisation and impairment of intangible assets excluding development costs
as reconciled below.
Adjusted Profit Before Tax is earnings before tax, amortisation and impairment
of intangibles assets excluding development costs, and exceptional items as
reconciled below. These measures are not defined performance measures in IFRS.
The Group's definition of these measures may not be comparable with similarly
titled performance measures and disclosures by other entities.
13. Alternative performance measures and other metrics (continued)
Reconciliation of Adjusted Operating Profit to Operating Loss
All figures in £000's Q1 2024 Q1 2023 FY 2023
(unaudited)
Restated
(audited)
(unaudited)
Revenue 40,473 54,422 169,476
Cost of sales (22,110) (30,024) (82,726)
Gross profit 18,363 24,398 86,750
Research and development costs (1,517) (1,551) (6,069)
Other operating costs (10,490) (11,568) (45,157)
Depreciation and impairment (6,249) (4,539) (18,409)
Amortisation of capitalised development costs (607) (617) (2,437)
Share of loss of equity accounted investees net of tax 318 56 (32)
Adjusted operating (loss)/profit (182) 6,179 14,646
Exceptional - restructuring, acquisition and disposal related items (517) (972) (3,904)
Amortisation and impairment of intangible assets excluding development costs (3,661) (4,885) (16,058)
Operating (loss)/profit (4,360) 322 (5,316)
Reconciliation of Loss Before Taxation to Adjusted Profit Before Tax
All figures in £000's Q1 2024 Q1 2023 FY 2023
(unaudited)
Restated
(audited)
(unaudited)
Loss before taxation (7,191) 553 (12,694)
Exceptional - restructuring, acquisition and disposal related items 517 972 3,904
Amortisation and impairment of intangible assets excluding development costs 3,661 4,885 16,058
Adjusted (loss)/profit before tax (3,013) 6,410 7,268
Other Metrics
All figures in £000's Q1 2024 Q1 2023 FY 2023
(unaudited)
Restated
(audited)
(unaudited)
Total R&D Investment
Research and development costs
- Continuing operations 1,517 1,551 6,069
- Discontinued operations - 12 59
Internal capitalised development costs 62 54 632
Total R&D investment 1,579 1,617 6,760
All figures in £000's Q1 2024 Q1 2023 FY 2023
(unaudited)
Restated
(audited)
(unaudited)
Adjusted EBITDA excluding fair value movement in biological assets
Adjusted EBITDA 6,674 11,335 35,492
Exclude fair value movement 793 1,154 103
Adjusted EBITDA excluding fair value movement in biological assets 7,467 12,489 35,595
13. Alternative performance measures and other metrics (continued)
Liquidity
A key financial covenant is a minimum liquidity of £10m, defined as cash plus
undrawn facilities.
All figures in £000's Q1 2024 Q1 2023 FY 2023
(unaudited)
Restated
(audited)
(unaudited)
Cash and cash equivalents 24,164 42,782 36,525
Undrawn bank facility 12,250 20,000 12,250
36,414 62,782 48,775
The undrawn bank facility relates to the RCF facility. At 31 December 2023,
£7.75m of the RCF was drawn (31 December 2022: £nil, 30 September 2023:
£7.75m), leaving £12.25m undrawn (31 December 2022: £20.0m, 30 September
2023: £12.25m).
14. Net debt
Net debt is cash and cash equivalents less loans and borrowings.
All figures in £000's Q1 2024 Q1 2023 FY 2023
(unaudited)
Restated
(audited)
(unaudited)
Cash and cash equivalents 24,164 42,782 36,525
Loans and borrowings (excluding lease liabilities) - current (8,473) (1,603) (8,478)
Loans and borrowings (excluding lease liabilities) - non-current (73,220) (79,067) (73,661)
Net debt excluding lease liabilities (57,529) (37,888) (45,614)
Lease liabilities - current (10,209) (14,624) (11,567)
Lease liabilities - non-current (6,812) (8,891) (8,293)
Net debt (74,550) (61,403) (65,474)
15. Post-balance sheet events
The Board believes that the current share price materially undervalues the
combined value of Benchmark's businesses and the long-term prospects of the
Company. Consequently, the Board announced on 22 January 2024 the decision to
undertake a formal review of the Company's strategic options. These options
include, but are not limited to, a potential sale of the Company as a whole or
of one or more individual business units, to establish whether bidders would
be prepared to offer a value for the Company that the Board considers
attractive relative to the Board's view of intrinsic value. The Company is
therefore commencing a targeted sales process. At this early stage of the
process, there are currently no deal or deals identified or underway and all
parts of the business continue to operate as usual.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END QRFGPUAPPUPCGRC